Home-based care coaching for managing COPD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial, conducted by the Icahn School of Medicine at Mount Sinai, evaluates a self-management support intervention for adults with chronic obstructive pulmonary disease (COPD), particularly targeting minoritized and low-income populations. Participants will receive comprehensive screening and management of barriers to COPD control, including home-based pulmonary rehabilitation and pre-emptive treatment for exacerbations. The study will compare the intervention's effectiveness against an attention control group, measuring outcomes such as medication adherence, COPD symptoms, and exercise capacity over 6 and 12 months. A total of 300 participants will be recruited from diverse communities in Manhattan, Queens, and Brooklyn.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥40 years
* Chart-documented COPD with GOLD classifications B or E based on CAT score and number of exacerbations with or without hospitalization determined by electronic health record (EHR) review. GOLD class B and E patients are at increased risk of activity limiting symptoms and exacerbation and are more likely to benefit from the intensive SAMBA-COPD intervention.
* Prescribed a long-acting muscarinic agonist (LAMA), long-acting beta-adrenergic receptor agonist (LABA), an inhaled corticosteroid (ICS), or any combination of these since much of the intervention's focus is on medication adherence.
* English or Spanish speaking

Exclusion Criteria:

* EHR documented dementia, as the research teams focus is on patients with capacity to independently perform self-care tasks.

Where it's running

• Ichan School of Medicine at Mount Sinai
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Alex Federman, MD, MPH — Ichan School of Medicine at Mount Sinai, The Mount Sinai Hospital
• Study coordinator: Alex Federman, MD, MPH
• Email: alex.federman@mountsinai.org
• Phone: 212-824-7565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Flutter therapy added to chest physiotherapy after CABG in COPD patients

  This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.

  Recruiting Foundation University Islamabad · Rawalpindi · NCT07875049

• TPB-based cadence exercise and breathing training for COPD patients

  A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.

  Recruiting Fu Jen Catholic University Hospital · New Taipei City, New Taipei City and 1 other locations · NCT07860008

• See how dynamic chest X-rays relate to COPD patterns and progression risk

  This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07762573

• Personalized mobile app warnings to reduce COPD flares

  A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.

  Recruiting at 4 sites Centers for Disease Control and Prevention, China · Beijing and 3 other locations · NCT07656142

• CLEAR model to predict when people with severe COPD can be taken off ventilatory support

  This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.

  Recruiting Assiut University · Asyut, Assuit Egypt · NCT07579052

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.